Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacodynamics
11 evidence topics · 9 sources
Adiponectin as a marker of PPARγ engagement: phase 1 multiple ascending dose study in healthy participants
Adiponectin, lipids, glucose, and fluid retention markers at day 28: phase 2a study in participants with type 2 diabetes on metformin
| Mean (SD) percent change from baseline at day 28 | Lanifibranor 400 mg (n=17) | Lanifibranor 800 mg (n=15) | Lanifibranor 1400 mg (n=15) | Placebo (n=14) |
|---|---|---|---|---|
| Triglycerides | “–19.7 (33.9)” | “–20.8 (23.5)” | “–31.7 (31.2)” | “–5.81 (27.6)” |
| HDL-C | “13.4 (15.3)” | “16.7 (17.2)” | “27.7 (25.9)” | “2.52 (12.2)” |
| Pro-insulin | “–26.7 (35.6)” | “–21.1 (45.0)” | “–37.4 (26.3)” | “–3.28 (49.9)” |
| Mean (SD) value reported for change from baseline at day 28 | Lanifibranor 400 mg (n=17) | Lanifibranor 800 mg (n=15) | Lanifibranor 1400 mg (n=15) | Placebo (n=14) |
|---|---|---|---|---|
| Ankle foot volume, cm3 | “3.75 (14.51)” | “–5.31 (15.51)” | “3.91 (11.14)” | “–5.42 (11.07)” |
| Body weight change at Day 28, kg | “0.55 (1.97)” | “0.11 (1.72)” | “0.94 (2.05)” | “–0.36 (2.68)” |
| Hemoglobin, g/L | “–5.63 (4.81)” | “–5.04 (6.75)” | “–5.96 (5.55)” | “–3.70 (5.29)” |
Pharmacodynamic biomarkers used for dose selection
Adiponectin, triglycerides, HDL cholesterol, and diastolic blood pressure after 24 weeks: NATIVE
“This manuscript reports the results of several secondary objectives of the NATIVE trial, that were prespecified in the protocol and the Statistical Analysis Plan (SAP), including the effect of lanifibranor 1200 mg/day and 800 mg/day versus placebo on CMH markers, evaluated after 24 weeks of treatment (EOT) compared to baseline, and for some markers also at TW4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Higher increase of adiponectin levels was observed in the lanifibranor 1200 mg (mean fold 4.5) compared to lanifibranor 800 mg (3.8) at EOT, 86% of patients on lanifibranor 800 mg had moderate (58%) or high (29%) increase and 95% of those on 1200 mg had moderate (52%) or high (42%) increase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With placebo only 10% had moderate, and none high increase (Supplementary Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adiponectin is a pleiotropic adipokine and PPARγ downstream mediator, while PPARα activity may affect adiponectin signaling through receptor upregulation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fasting total serum triglycerides (TG) levels decreased significantly with lanifibranor compared to placebo, with an AMD at EOT of −0.5 mmol/L (95%CI: −0.8 to −0.3, equivalent to −44.3 mg/dL, p < 0.001) with both lanifibranor 1200 mg and 800 mg groups (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fasting high density lipoprotein cholesterol (HDL-C) increased significantly at treatment week 4 (TW4), maintained until EOT: patients receiving lanifibranor 1200 mg and 800 mg had an AMD at EOT of 0.10 mmol/L (95%CI: 0.03 to 0.16, p = 0.003, equivalent to 3.9 mg/dL) and 0.16 mmol/L (95%CI: 0.09 to 0.22, p < 0.001, equivalent to 6.2 mg/dL), respectively (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No significant LDL-C change was observed with either lanifibranor dose versus placebo (Table 1, Fig. 1C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From TW4 and maintained during treatment, diastolic BP (DBP) decreased with both lanifibranor doses (AMD at EOT was −2.5 mmHg [95%CI: −5.5 to 0.6, p = 0.110] with lanifibranor 1200 mg and −3.9 mmHg [95%CI: −6.9 to −0.9, p = 0.012] with 800 mg, [Table 1, Fig. 1I]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Systolic BP did not change significantly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NT-proBNP, hemoglobin, and the PPARγ class history of edema and heart failure
“While PPARγ-associated weight gain is thus indicative of maturation of adipose tissue, some contributing effect on fluid retention is suggested by the treatment effect on NT-proBNP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Past pure PPARγ agonists such as the thiazolidinediones pioglitazone and rosiglitazone are effective for glycemic control and improving IR, but also have been associated with an increased risk of edema and heart failure” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no clinical evidence for congestion in patients on lanifibranor in NATIVE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Important risks identified for the PPAR agonist class
Plasma volume and cardiac effects in rats compared with rosiglitazone, muraglitazar, and tesaglitazar
Hepatic, muscle, and adipose tissue insulin sensitivity by clamp: participants with type 2 diabetes and MASLD
Liver sinusoidal endothelial cell capillarisation in NATIVE liver biopsies
“We analysed CD34 expression, a marker of LSEC capillarisation, on liver biopsies from patients considered for inclusion in the NATIVE trial at baseline (n = 249), and after 24 weeks of placebo or lanifibranor (n = 173).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with MASH randomised into the NATIVE trial, 24-week treatment with lanifibranor at both dosages had no effect on the density of CD34-positive vessels (Fig. 5A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Improvement in periportal score was more common in patients treated with lanifibranor than in those treated with placebo, with a dose–response effect (placebo: 7.5%. lanifibranor 800 mg: 18.5%. lanifibranor 1,200 mg: 23.2%. p = 0.025, Fig. 5C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In both patients and rats with MASLD, lanifibranor treatment was associated with improvement in liver endothelial phenotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Portal pressure and fibrosis in cirrhotic rat models
“TAA-cirrhotic rats receiving lanifibranor showed significantly lower portal pressure compared with vehicle-treated animals (-15%; p = 0.003) without decreasing portal blood flow, indicating improved hepatic vascular resistance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, lanifibranor-treated TAA-rats showed decreased ascites, improved LSEC and HSC phenotypes, ameliorated hepatic microvascular function, reduced hepatic inflammation, and significant fibrosis regression (-32%; p = 0.020).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote